Stone Christopher Lewis 4/A
4/A · PDL BIOPHARMA, INC. · Filed Apr 16, 2019
Insider Transaction Report
Form 4/AAmended
Stone Christopher Lewis
VP and General Counsel
Transactions
- Award
Stock Option (right to buy)
2019-03-28+833,333→ 833,333 totalExercise: $3.72Exp: 2029-03-28→ Common stock (833,333 underlying)
Footnotes (2)
- [F1]The number of shares included in the original April 1, 2019 Form 4 filing was incorrect and the Company is filing this amendment to correct the number of shares in the award grant.
- [F2]The stock options will vest as follows: (a) 25% of the shares subject to the option shall vest on the one year anniversary of January 1, 2019 and (b) 75% of the shares subject to the option shall vest on a monthly basis pro rata over the thirty-six (36) months following the one year anniversary of January 1, 2019, provided that the recipient's continuous service has not terminated prior to the applicable vesting date, subject to earlier vesting upon a change in control and certain qualifying terminations of employment provided in the severance agreement between the issuer and the recipient.